Clinical Trial Update: SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures [Phase 2]

View source ↗

Summary

An open-label extension study of SPN-817 in adults with focal onset seizures is in Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Onset Seizures

Drugs mentioned

• SPN-817 (SPN-817)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Focal Onset Seizures | Phase 2 | Status: RECRUITING